NCT04943848 — Ann & Robert H Lurie Children's Hospital of… cancer immunotherapy trial
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Registry record
| Registry ID | NCT04943848 ↗ |
|---|---|
| Lead sponsor | Ann & Robert H Lurie Children's Hospital of Chicago |
| Collaborators | Dana-Farber Cancer Institute, Children's Hospital of Orange County, University of Calgary |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant |
| Enrollment | 36 participants (target) |
| Start date | 2022-01-10 |
| Primary completion | 2026-09 (est.) |
| Last registry update | 17 Mar 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04943848), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT04943848?
NCT04943848 (rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG) is registered on ClinicalTrials.gov as Phase 1, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
Is NCT04943848 recruiting?
As of the 2026-03-17 registry update, NCT04943848 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04943848?
The lead sponsor is Ann & Robert H Lurie Children's Hospital of Chicago. Collaborators: Dana-Farber Cancer Institute, Children's Hospital of Orange County, University of Calgary.
What condition does NCT04943848 study?
The registered conditions are Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant. Primary completion is listed as 2026-09 (estimated).
Are results available for NCT04943848?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04943848.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.